Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$AIKI THANK YOU
RE;
Hi mick...Hope all is well...my limited access to only 15 posts a day do not allow me to respond to many posts...sorry...
Hi mick...Hope all is well...my limited access to only 15 posts a day do not allow me to respond to many posts...sorry...
$aiki $1.03 ^ 0.09 (9.57%)
Volume: 6,611,148 @07/17/20 7:59:44 PM EDT
$AIKI , hi dare my friend
re;
AIKI...$1.03...Chart turning Very Bullish on the Consolidation Channel Breakout as the Bollinger Bands get stretched...adding on this Bullish Chart...
AIKI...tested the Break/Hold of the 200ma 3 times and failed...Monday it will Break/Hold the 200ma as well as flip the Psar to a Bullish Buy position on the Breakout...imo...we shall see...
georgie18 Saturday, 06/06/20 06:23:21 AM
Re: Citrati post# 7743 0
Post #
7744
of 7895
AIKI...73...Consolidation Channel Breakout setting up here on the Bollie Squeeze...as the Psar is ready to flip to a Bullish Buy Position...
As of May 13, 2020, there were 34,920,219 shares of the Company’s common stock issued and outstanding.
https://www.otcmarkets.com/filing/html?id=14148986&guid=JvaHUnzRuvrmGth
Chart...http://schrts.co/nxCbhCuz
Been accumulating AIKI for months also collected a nice Divvy of HOTH shares currently priced at $2.80...
$AIKI i see $1.06 a,h, trading
re;
A good post on AIKI, $AIKI needs to break $1.12 it will be $3
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156972130
AIKI...$1.03...Chart turning Very Bullish on the Consolidation Channel Breakout as the Bollinger Bands get stretched...adding on this Bullish Chart...
AIKI...tested the Break/Hold of the 200ma 3 times and failed...Monday it will Break/Hold the 200ma as well as flip the Psar to a Bullish Buy position on the Breakout...imo...we shall see...
georgie18 Saturday, 06/06/20 06:23:21 AM
Re: Citrati post# 7743 0
Post #
7744
of 7895
AIKI...73...Consolidation Channel Breakout setting up here on the Bollie Squeeze...as the Psar is ready to flip to a Bullish Buy Position...
As of May 13, 2020, there were 34,920,219 shares of the Company’s common stock issued and outstanding.
https://www.otcmarkets.com/filing/html?id=14148986&guid=JvaHUnzRuvrmGth
Chart...http://schrts.co/nxCbhCuz
Been accumulating AIKI for months also collected a nice Divvy of HOTH shares currently priced at $2.80...
Great sign, going higher after hours.
Then we're looking at big $$$'s...
Yes hope so. We need some major news like a drug approval.
Hopefully this thing goes up in after-hours big time.
Closed $1.03. Closing above $1 is a good sign to upside. IMO.
Thank you I feel the same about AIKI. That’s why I bought in. Good trading to you
Double our money next week probably triple have a good weekend *AIKI* my play of the week next week
A good post on AIKI, "$AIKI needs to break $1.12 it will be $3
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156972130
AIKI back up over $1
AIKI $4 TARGET PRICE WOOHOOOOOOOOOOOOOOO
AIkido Pharma, Inc. Shares Outstanding 34,920,200 Float 32,952,167
Insider Ownership 5.64%
Insitutional Ownership 18.10%
?
$AIKI THANK YOU VERY MUCH
RE;
Picked up a few shares. Read this post.
$AIKI just added 7,777 to my 27,777 under .90 -- Got a feeling we see $3's Plus soon !!! Good luck all
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156953075
Picked up a few shares. Read this post.
$AIKI just added 7,777 to my 27,777 under .90 -- Got a feeling we see $3's Plus soon !!! Good luck all
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156953075
$AIKI Alkido Pharma Inc (AIKI)
1.0008 ? 0.1083 (12.13%)
Volume: 11,285,444 @07/16/20 1:44:22 PM EDT
Bid Ask Day's Range
1.0 1.01 0.8631 - 1.05
AIKI Detailed Quote
$AIKI VOLUME ALERT !!!!!
$AIKI READING
RE;
NEW YORK, July 9, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on its effort to identify compounds to potentially address the COVID-19 pandemic.
As previously announced, on April 13, 2020, AIkido executed a Master License Agreement with the University of Maryland, Baltimore ("UMB"), covering certain antiviral compounds discovered by UMB.
Recently, the researchers at UMB, including Matthew Frieman, PhD, Associate Professor of Microbiology and Immunology at the University of Maryland School of Medicine (UMSOM), Alexander MacKerell,
PhD, Professor of Pharmaceutical Sciences at the University of Maryland School of Pharmacy, and Stuart Weston, PhD, Postdoctoral Fellow at UMSOM, have identified a human protein complex
(called the SKI complex) that is important for replication of several viruses including
Influenza, COVID-19, SARS1, MERS, SARS2, Ebola and Marburg.
Using a computer modeling approach called SILCS from SilcsBio LLC, chemical compounds were identified that are predicted to bind to a pocket on a human protein in this complex.
These compounds were tested for their ability to block replication of the Influenza virus in human cells, from which several active compounds were found.
These compounds were then tested against the other viruses and found to block replication of these as well.
Utilizing the information gleaned from this initial research and the power of the SILCS technology combined with machine learning tools,
the researchers are currently identifying compounds with chemical structures similar to the active compounds and testing them to find
ones that work better at blocking virus replication.
"This is encouraging progress,
demonstrating the importance of machine learning to accelerate pharmaceutical research," commented Anthony Hayes,
CEO of AIkido.
"Legacy processes, involving manually testing potentially thousands of compounds, are slower and potentially more expensive.
Utilizing a combination of a physics-based approach and machine learning, our partners are able to significantly narrow the range of potential compounds to test,
accelerating efforts and significantly reducing costs.
The ultimate goal is to create a new compound that blocks replication
of a wide variety of viruses in humans that will be an effective drug for the treatment of known viral infections as well as those that may arise in the future."
Something's brewing at AIKI, insiders must have some info maybe?
Indeed which surprises me a bit
Pretty low float.
Share Structure
Market Cap Market Cap
4,306,802
07/15/2020
Authorized Shares
200,000,000
03/02/2020
Outstanding Shares
4,825,549
03/02/202
NEW YORK, July 9, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on its effort to identify compounds to potentially address the COVID-19 pandemic. As previously announced, on April 13, 2020, AIkido executed a Master License Agreement with the University of Maryland, Baltimore ("UMB"), covering certain antiviral compounds discovered by UMB.
Recently, the researchers at UMB, including Matthew Frieman, PhD, Associate Professor of Microbiology and Immunology at the University of Maryland School of Medicine (UMSOM), Alexander MacKerell, PhD, Professor of Pharmaceutical Sciences at the University of Maryland School of Pharmacy, and Stuart Weston, PhD, Postdoctoral Fellow at UMSOM, have identified a human protein complex (called the SKI complex) that is important for replication of several viruses including Influenza, COVID-19, SARS1, MERS, SARS2, Ebola and Marburg. Using a computer modeling approach called SILCS from SilcsBio LLC, chemical compounds were identified that are predicted to bind to a pocket on a human protein in this complex. These compounds were tested for their ability to block replication of the Influenza virus in human cells, from which several active compounds were found. These compounds were then tested against the other viruses and found to block replication of these as well. Utilizing the information gleaned from this initial research and the power of the SILCS technology combined with machine learning tools, the researchers are currently identifying compounds with chemical structures similar to the active compounds and testing them to find ones that work better at blocking virus replication.
"This is encouraging progress, demonstrating the importance of machine learning to accelerate pharmaceutical research," commented Anthony Hayes, CEO of AIkido. "Legacy processes, involving manually testing potentially thousands of compounds, are slower and potentially more expensive. Utilizing a combination of a physics-based approach and machine learning, our partners are able to significantly narrow the range of potential compounds to test, accelerating efforts and significantly reducing costs. The ultimate goal is to create a new compound that blocks replication of a wide variety of viruses in humans that will be an effective drug for the treatment of known viral infections as well as those that may arise in the future."
My pleasure! It's time for them to announce something huge already.
Has been a while we had no big moves.
$AIKI reading thank you
re;
They have many in the pipelines. AIKI, HOTH, finding cure for COVID-19 would be a good one for starters. Any other ones would be good.
They have many in the pipelines. AIKI, HOTH, finding cure for COVID-19 would be a good one for starters. Any other ones would be good.
$AIKI it has proven better than w.h.o. is touting
$AIKI WHICH ONES ?????
RE;
We need to hear from company, finalized approved products. Hopefully soon!
$AIKI THANK YOU, I WISHED IT DID.
RE;
Hydroxychloroquine has nothing to do with AIKI.
Hydroxychloroquine has nothing to do with AIKI.
We need to hear from company, finalized approved products. Hopefully soon!
Hydroxychloroquine. What about it?
$AIKI READING INFO http://www.Benzinga.com
RE;
Options Trade Ideas from Benzinga
In this market, there's never been a better time to profit with options. Get Benzinga Options: Starter Edition to follow Nic Chahine's high-conviction options trades. Click here to subscribe.
AIkido Pharma is a U.S.-based biotechnology company. The company is engaged in the development of small-molecule anti-cancer therapeutics. The company's drug portfolio includes therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).
Aikido Pharma's stock was trading up 5.77% at 92 cents on Thursday during the time of publication. The stock has a 52-week high of $5.52 and a 52-week low of 48 cents.
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
$AIKI , THANK YOU FER INFO. YA HAVE DA LINK ?????
RE;
Aikido Pharma Announces Key Progress In Computational Approaches To Identify Virus Treatments, Including Coronavirus
Benzinga Newsdesk , Benzinga Staff Writer FOLLOW
July 09, 2020 1:32pm 1 min read Comments
This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.
Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.
Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.
Followers
|
156
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
8287
|
Created
|
12/30/04
|
Type
|
Free
|
Moderators |
Kucera Paper Lipid Nucleoside Conjugates for the Treatment of Cancer
Kucers & Pardee Paper Improving Nucleoside Analogs via Lipid Conjugation
The Phospholipid Gemcitabine Conjugate, KPC34, is a Novel Treatment for Leukemia
Short-term Toxicity Study of DHA-dFdC
AIkido Pharma Inc. seeks to enhance shareholder value not only through exceptional business performance and practices,
but also through responsible and effective communication with its shareholders. The latest company information relevant to the individual
and institutional investor includes stock price and history, upcoming events and presentations and financial documents.
AIkido Pharma Inc. is traded on the Nasdaq under the ticker symbol AIKI.
AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics.
The Spherix platform contains patented technology from leading universities and researchers and we seek to develop
our innovative drugs through strong partnership with world renowned institutions, such as The University of Texas and Wake Forest University.
Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).
Our pancreatic treatment has shown positive preclinical results for inhibiting pancreatic tumor growth in clinically relevant transgenic mouse models.
The drug has also demonstrated the potential to overcome tumor cell resistance to current chemotherapeutic drugs.
Our AML drug is a next generation targeted therapeutic designed to overcome multiple resistance mechanisms observed with the current standard of care.
In addition, we are constantly seeking to grow our pipe to treat unmet medical needs in oncology.
https://ir.aikidopharma.com/stock-information/
$AIKI Spherix Incorporated, a biotechnology company,focuses on developing small-molecule anti-cancer therapeutics.
Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.
The company's platform consists of patented technology from leading universities and researchers and in the process of developing an
innovative therapeutic drug platform through partnerships with world renowned educational institutions, including The University of Texas at
Austin and Wake Forest University.
It has a scientific research agreement with The University of Texas Southwestern Medical Center to use machine learning to find genetic
markers in people that indicate an increased risk of developing pancreatic cancer.
Spherix Incorporated was founded in 1967 and is based in New York, New York.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |